Breast Cancer

Authoritative sources

• Wikidata (Q128581)
• MeSH (D001943)
• Wikipedia

Evidence base

• Randomized Controlled Trial · 2004 · Landmark

  Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy

  JAMA · Anderson GL, Limacher M, Assaf AR, et al.

  For women without a uterus, estrogen-only therapy showed a much more favorable risk profile than the combined therapy arm.

• Randomized Controlled Trial · 2002 · Landmark

  Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women

  JAMA · Rossouw JE, Anderson GL, Prentice RL, et al. (Writing Group for the Women's Health Initiative)

  The Women's Health Initiative was the landmark trial that reshaped how doctors prescribe hormone therapy after menopause. Later re-analyses showed the risk profile is very different for women who start HRT closer to menopause.

• Randomized Controlled Trial · 2026

  Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer

  The New England journal of medicine · Tolaney SM, Jiang Z, Zhang Q, Barroso-Sousa R, et al.

• Randomized Controlled Trial · 2025

  Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

  The New England journal of medicine · Jhaveri KL, Neven P, Casalnuovo ML, Kim SB, et al.

• Randomized Controlled Trial · 2024

  Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

  The New England journal of medicine · Schmid P, Cortes J, Dent R, McArthur H, et al.

• Randomized Controlled Trial · 2024

  Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

  The New England journal of medicine · Bardia A, Hu X, Dent R, Yonemori K, et al.

• Randomized Controlled Trial · 2024

  Ribociclib plus Endocrine Therapy in Early Breast Cancer

  The New England journal of medicine · Slamon D, Lipatov O, Nowecki Z, McAndrew N, et al.

• Randomized Controlled Trial · 2023

  Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

  The New England journal of medicine · Turner NC, Oliveira M, Howell SJ, Dalenc F, et al.

• Randomized Controlled Trial · 2022

  Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Bidard FC, Kaklamani VG, Neven P, Streich G, et al.

• Randomized Controlled Trial · 2022

  Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

  The New England journal of medicine · Modi S, Jacot W, Yamashita T, Sohn J, et al.

• Randomized Controlled Trial · 2022

  Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

  The New England journal of medicine · Cortés J, Kim SB, Chung WP, Im SA, et al.

• Randomized Controlled Trial · 2021

  Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  The New England journal of medicine · Bardia A, Hurvitz SA, Tolaney SM, Loirat D, et al.

Where Breast Cancer appears on Kindr Health